CERO THERAPEUTICS HOLDINGS, INC.

We are an innovative immunotherapy company focused on developing next-generation engineered T cell therapeutics for cancer treatment. Our proprietary T cell engineering approach integrates characteristics of both innate and adaptive immunity into a single therapeutic construct, aiming to engage the body's full immune system for optimized cancer therapy. Our novel cellular immunotherapy platform redirects patient-derived T cells to eliminate tumors by employing both cytotoxic and phagocytic mechanisms to destroy cancer cells, creating Chimeric Engulfment Receptor T ("CER-T") cells. Our lead molecule is CER-1236, an autologous T-cell product targeting the TIM-4 ligand tumor antigen. We believe CER-1236 will be active in both hematological malignancies and solid tumors. On November 14, 2024, the FDA cleared our Investigational New Drug Application ("IND") for CER-1236 after a brief clinical hold due to insufficient nonclinical data, which was lifted following additional in vitro experiments. In May 2025, we initiated our Phase 1 clinical trial for CER-1236 in patients with acute myeloid leukemia ("AML"). This first-in-human, multi-center, open label, Phase 1/1b study evaluates the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory AML, AML in remission with measurable residual disease, or newly diagnosed patients with TP53 mutated MDS/AML or AML. On March 27, 2025, the FDA accepted our second IND application for CER-T cell therapy in non-small cell lung cancer ("NSCLC") and ovarian cancer.